As an alternative therapeutic approach for EBV-PTLD, NKG2D CAR-T combining with other types of CAR therapy could prevent immune escape from antigen loss and immune suppression and provide additional treatment options for patients. This evidence concerns the gene KLRK1 and post-transplant lymphoproliferative disease.